From a strictly lolbertarian perspective, good vaccines are a shitty business to be in, shitty vaccines are a great business to be in.
Real vaccine: capital intensive, may or may not succeed despite best efforts, side effects will probably be present, requires that you produce insane amounts and successfully market to every potential customer or it doesn’t work. In the best case where you actually achieve maximum distribution, the pathogen is gone, and you’ll never sell another one, so if you didn’t profit in the first rush, you’ll never see your money again.
Alex jones colloidal silver: I tell you it works, if you’re not dead in a year, you’re obviously another satisfied customer, here buy another bullshit vaccine from me.
Second product is better for the seller than the first, capital investment is zero, marketing cost can find efficiencies in cost per customer, repeat business is probable.
If you can come up with a business model that makes good vaccines profitable in the current environment, absent aggressive government subsidies, you should start that business and shout your model from the rooftops, because most people in biotech would (angrily) agree with my summary.
Source: have thrown this at many biotech executives and government officers involved in vaccine procuremrnt. Have gotten head nodding.
From a strictly lolbertarian perspective, good vaccines are a shitty business to be in, shitty vaccines are a great business to be in.
Real vaccine: capital intensive, may or may not succeed despite best efforts, side effects will probably be present, requires that you produce insane amounts and successfully market to every potential customer or it doesn’t work. In the best case where you actually achieve maximum distribution, the pathogen is gone, and you’ll never sell another one, so if you didn’t profit in the first rush, you’ll never see your money again.
Alex jones colloidal silver: I tell you it works, if you’re not dead in a year, you’re obviously another satisfied customer, here buy another bullshit vaccine from me.
Second product is better for the seller than the first, capital investment is zero, marketing cost can find efficiencies in cost per customer, repeat business is probable.
If you can come up with a business model that makes good vaccines profitable in the current environment, absent aggressive government subsidies, you should start that business and shout your model from the rooftops, because most people in biotech would (angrily) agree with my summary.
Source: have thrown this at many biotech executives and government officers involved in vaccine procuremrnt. Have gotten head nodding.